Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.
Stephens
T C
TC
ZENECA Pharmaceuticals, Macclesfield, Cheshire, UK.
Smith
M N
MN
Waterman
S E
SE
McCloskey
M L
ML
Jackman
A L
AL
Boyle
F T
FT
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005492:Folic Acid / Q000031:analogs & derivatives; D005493:Folic Acid Antagonists / Q000627:therapeutic use / Q000633:toxicity*; D007940:Leukemia L5178 / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D008811:Mice, Inbred DBA; D009154:Mutation; D011799:Quinazolines / Q000627:therapeutic use / Q000633:toxicity; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000627:therapeutic use / Q000633:toxicity; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013876:Thiophenes; D005492:Folic Acid; D013940:Thymidylate Synthase; C068874:raltitrexed